Quarry LP’s Travere Therapeutics TVTX Stock Holding History

Quarry LP’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$571K	Sell	10,045 -3,825	-28%	-$170K	0.05%	137
2026 Q1	$412K	Buy	+13,870	New	+$415K	0.07%	186
2025 Q4	–	Sell	-14,960	Closed	-$358K	–	2628
2025 Q3	$358K	Buy	14,960 +7,960	+114%	+$150K	0.08%	233
2025 Q2	$104K	Sell	7,000 -8,000	-53%	-$133K	0.02%	546
2025 Q1	$269K	Buy	15,000 +3,000	+25%	+$60.9K	0.06%	254
2024 Q4	$209K	Buy	12,000 +4,500	+60%	+$79.6K	0.03%	241
2024 Q3	$105K	Buy	+7,500	New	+$78.1K	0.03%	413
2024 Q2	–	Sell	-10,000	Closed	-$77.1K	–	2108
2024 Q1	$77.1K	Buy	10,000 +5,500	+122%	+$46.4K	0.01%	297
2023 Q4	$40.5K	Sell	4,500 -5,500	-55%	-$40K	0.01%	400
2023 Q3	$89.4K	Buy	+10,000	New	+$141K	0.02%	219

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quarry LP's TVTX Position: Q2 2026 in Review

Quarry LP reduced its Travere Therapeutics (TVTX) stake by 28% in Q2 2026, selling an estimated $170K and leaving 10,045 shares worth $571K. The position accounts for 0.05% of the portfolio, ranked #137.

Quarry LP first reported a position in TVTX in Q3 2023 and has held it in 10 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Quarry LP held 10,045 shares of Travere Therapeutics worth $571K as of Q2 2026.
Quarry LP sold 3,825 Travere Therapeutics shares in Q2 2026, an estimated $170K.
Travere Therapeutics made up 0.05% of Quarry LP's portfolio in Q2 2026, its #137 holding.
Quarry LP first reported a position in Travere Therapeutics in Q3 2023 and has held it in 10 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.